Medicinal Mushrooms and Drug Interactions: A Complete Guide

Mushrooms & Drug Interactions

77 clinical studies

A 2020 systematic review found no adverse pharmacological interactions between mushroom extracts and cytotoxic chemotherapy drugs across 77 clinical trials, while also documenting immune and quality-of-life benefits.

Lam et al., Chinese Medicine, 2020

1 RCT

controlled trial combining a specific mushroom with a specific drug

7 CYP enzymes

inhibited by reishi triterpenoids in laboratory studies

Most risks

theoretical: based on lab data, not confirmed clinical interactions

Lam et al., Chinese Medicine, 2020

View as image ↗

Ask most pharmacists about medicinal mushrooms and drug interactions, and you'll get a careful hedge: probably be careful with those. Search the internet and you'll find wellness sites that either ignore the question or offer a boilerplate disclaimer with no mechanism, no dose context, and no citation.

The actual research picture is more interesting than either response. For most drug classes, the concern about medicinal mushrooms is based on in vitro evidence (studies conducted in test tubes and cell cultures, not in people). That matters because the concentration of a compound needed to inhibit an enzyme in a lab dish is often ten to a hundred times higher than what actually reaches the bloodstream from a supplement.

That said, some concerns are specific enough to take seriously, and one drug class has been tested in an actual clinical trial. This guide examines each drug class with the evidence it deserves, being honest about where the data is solid and where it is extrapolated from the lab.

Because how much of a mushroom's bioactive compounds you actually absorb depends on how it was extracted and processed, see how mushroom extraction methods work for the background on that.

Mushrooms and Drug Interactions at a Glance

Most people searching this topic want a clear summary of which mushrooms interact with which medications. Here is one, organized by drug class, with honest evidence ratings.

Blood thinners (warfarin, aspirin, clopidogrel) Concern: moderate (in vitro). Reishi and lion's mane inhibit platelet aggregation in laboratory studies.^[4] No documented clinical cases of mushrooms increasing bleeding in people taking anticoagulants appear in the published literature, but the mechanism is plausible enough to warrant awareness in people whose anticoagulation is tightly monitored. See Mushrooms and Blood Thinners: Interaction Risks for the full breakdown.

Diabetes medications (metformin, sulfonylureas, insulin) Concern: low to moderate, with one clinical study. The only controlled trial combined Agaricus blazei with metformin and gliclazide and found improved insulin resistance with no hypoglycemia events.^[2] The risk of excessive blood sugar lowering depends on which diabetes drug class is involved. See Mushrooms and Diabetes Medications: Hypoglycemia Risk.

CYP450 enzyme substrates (statins, many cancer drugs, benzodiazepines) Concern: preclinical. Reishi triterpenoids inhibit several of the liver's drug-processing enzymes in laboratory studies, including CYP3A4 and CYP2C9, which together handle a large fraction of common medications.^[1] Whether supplement doses produce concentrations high enough to matter in people is unresolved. See Mushrooms and Cytochrome P450: Do They Affect Drug Metabolism?.

Immunosuppressants (cyclosporine, tacrolimus) Concern: theoretical. Immune-stimulating mushrooms like turkey tail and reishi could theoretically counteract drugs designed to suppress immune function in transplant patients. For cancer patients on chemotherapy, a different form of immune suppression, a 2020 systematic review of 77 clinical studies found no adverse interactions and generally documented benefit.^[3] See Mushrooms and Immunosuppressants: Safety Considerations.

Chemotherapy (cytotoxic anticancer drugs) Concern: low (reassuring data across 77 clinical studies). See the dedicated section below.

SSRI antidepressants with psilocybin mushrooms Concern: substantial, with a specific mechanism. This concern does not apply to functional mushrooms.

The Evidence Problem: Why Most Interaction Warnings Come From Lab Data

Before examining each drug class, it is worth understanding why so many mushroom-drug interaction warnings are hedged with uncertainty.

Most supplement-drug interactions are identified first in vitro. Researchers expose liver enzymes, platelet preparations, or cell cultures to concentrated extracts and measure the effect. When an extract inhibits a liver enzyme in a test tube, that finding gets reported as a potential drug interaction concern.

The gap between a lab finding and a confirmed clinical interaction is significant. In Li et al.'s 2024 study, the most potent Ganoderma compound inhibited the liver enzyme CYP3A4 with an IC50 (the concentration needed to halve enzyme activity) of 4.78 micromolar.^[1] Published measurements of actual triterpenoid levels in human blood after oral supplementation report concentrations roughly ten to a hundred times lower. Whether that gap means no risk or merely reduced risk is not yet settled.

This does not mean in vitro warnings should be dismissed. The CYP3A4 concern for reishi is biologically plausible. The platelet aggregation concern for lion's mane makes mechanistic sense. These are real signals worth tracking. But a signal from a test tube is not the same as a documented clinical interaction.

The one exception in the research literature is Hsu 2007, discussed below. That is the only published RCT combining a specific mushroom with a specific drug in human patients.

Reishi and CYP450: Strong Lab Data, Uncertain Meaning at Supplement Doses

The liver contains a family of enzymes called cytochrome P450 (CYP450) that process the majority of medications. When something slows these enzymes down, drugs that rely on them for clearance build up to higher concentrations in the blood. When something speeds them up, drugs clear faster and lose effect.

Li et al. published a 2024 study in Frontiers in Pharmacology evaluating 66 individual triterpenoid compounds from reishi against seven CYP enzyme subtypes: CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, and 3A4.^[1] One compound inhibited CYP3A4, 2B6, 2C9, and 2C19 simultaneously, with IC50 values ranging from 4.78 to 25.28 micromolar. The researchers confirmed pharmacokinetic effects in a rat model using the same compounds.

CYP3A4 is clinically significant because it metabolizes an estimated 30 to 50 percent of commonly prescribed drugs, including statins, many blood pressure medications, certain cancer drugs, and benzodiazepines. CYP2C9 metabolizes warfarin, the blood thinner with the narrowest therapeutic window of any routinely prescribed medication.

The critical question that Li 2024 could not answer: whether standard reishi supplement doses produce triterpenoid blood concentrations close to the inhibitory concentrations observed in the lab. The researchers noted that clinical relevance at typical supplement doses remains unknown. Until human pharmacokinetic studies measure actual triterpenoid concentrations after supplementation, the CYP450 concern for reishi stays in the category of biologically plausible but unconfirmed in people.

Mushrooms and Blood Thinners: What the Platelet Research Shows

Kozarski et al. conducted a 2019 in vitro evaluation of multiple mushroom species' effects on human platelet function and blood coagulation.^[4] Both reishi and lion's mane extracts inhibited platelet aggregation in a species- and extract-dependent pattern. The effect was particularly apparent for the pathway triggered by collagen exposure, which is one of the main signals the body uses to start forming clots.

Both of the study's key limitations deserve emphasis: the work was done in vitro, and the concentrations were not calibrated to human-relevant doses from oral supplementation. The extracts were applied directly to platelet preparations.

Even so, the finding is relevant in a specific context. People taking anticoagulants like warfarin operate within a therapeutic range where clot-preventing activity must stay between insufficient and excessive. Any additive effect on platelet function, even modest, could shift the balance. Warfarin monitoring via INR testing would detect a meaningful shift, but only if the testing is happening and the prescriber is aware of the supplement.

For a breakdown of which mushroom species carry the most evidence for blood-thinning effects and how the CYP2C9 warfarin metabolism pathway adds a separate mechanism, see Mushrooms and Blood Thinners: Interaction Risks. For the broader cardiovascular biology, see Mushrooms and Blood Clotting: Anticoagulant and Antiplatelet Research.

The One Clinical Study: Agaricus Blazei, Metformin, and Insulin Resistance

Among all the research on medicinal mushrooms and drug interactions, Hsu et al. 2007 is the only published RCT testing a specific mushroom with a specific drug regimen in human patients.^[2]

Hsu's team randomized patients with type 2 diabetes who were already taking metformin and gliclazide. One group added Agaricus blazei Murill extract. The other received placebo. The mushroom group showed significantly improved insulin resistance compared to controls. No hypoglycemia events were reported in either group.

The gliclazide detail matters. Sulfonylureas like gliclazide work by stimulating insulin release whether or not blood sugar is elevated. That mechanism carries inherent hypoglycemia risk. Adding a glucose-lowering mushroom extract to that regimen produced no hypoglycemia in this trial, which was a meaningful finding, not a guaranteed one.

The limitations are real: this was one trial, one mushroom species, one drug combination, one patient population. The results cannot be extended to all mushrooms, all diabetes drugs, or all diabetic patients. But this is the only controlled clinical evidence in a field where nearly everything else is extrapolated from lab and animal data.

The practical point: additive glucose-lowering effects are the primary concern when combining mushrooms with diabetes medications. How serious that concern is depends entirely on which drug class is involved. For the full stratification, see Mushrooms and Diabetes Medications: Hypoglycemia Risk.

Mushrooms and Chemotherapy: 77 Clinical Studies, No Adverse Interactions

The combination of medicinal mushrooms with cancer treatment is one of the most studied areas in integrative oncology, and the findings are more reassuring than the standard caution language suggests.

Lam et al. conducted a 2020 systematic review in Chinese Medicine examining herb-drug interactions between reishi and turkey tail combined with cytotoxic anticancer drugs.^[3] The review covered 213 studies total, 77 of which were clinical trials in people. Across all 77 clinical studies, no adverse pharmacological interactions were documented. The mushroom groups showed reduced chemotherapy-induced immune suppression, improved immune cell counts, better quality of life, and in some analyses, better survival outcomes.

This is a substantial evidence base. The combination of turkey tail polysaccharide K (PSK) with standard cytotoxic chemotherapy regimens has been studied more rigorously than nearly any other supplement-drug pairing in oncology.

One distinction that the Lam 2020 review cannot resolve: cancer patients receiving chemotherapy are experiencing treatment-induced immune suppression, a temporary state. Organ transplant patients take immunosuppressants permanently to prevent their immune system from attacking the transplanted organ. Mushrooms combined with chemotherapy-induced suppression appears safe and often beneficial. Mushrooms combined with transplant-specific immunosuppressants (cyclosporine, tacrolimus) is an entirely separate situation with no comparable clinical evidence.

There is also an independent mechanism at play for cyclosporine specifically. Cyclosporine is metabolized by CYP3A4, the same enzyme that reishi triterpenoids inhibit in laboratory studies. If reishi inhibits CYP3A4 at clinically meaningful concentrations in people, it could raise cyclosporine blood levels through a purely pharmacokinetic pathway, separate from any immune interaction. For the full transplant patient analysis, see Mushrooms and Immunosuppressants: Safety Considerations.

SSRI Antidepressants and Psilocybin Mushrooms: A Different Risk Category

Everything discussed so far concerns functional or medicinal mushrooms: lion's mane, reishi, turkey tail, chaga, maitake, cordyceps. These contain bioactive compounds that influence the immune system, liver enzymes, or platelet function.

Psilocybin mushrooms are a different category. Psilocybin, the active compound in psychedelic mushrooms, works by activating serotonin receptors in the brain. SSRIs (the antidepressant class that includes fluoxetine, sertraline, and escitalopram) increase serotonin availability through a different mechanism. Combining them creates excess serotonin activity, which can cause serotonin syndrome: a serious condition with symptoms ranging from agitation and rapid heart rate to severe neuromuscular effects.

Jolliff et al. published a 2024 analysis of Reddit posts describing self-reported SSRI and psychedelic mushroom combinations.^[5] Posts described a range of experiences, from blunted psychedelic effects (the most commonly reported outcome) to adverse reactions including agitation and physical symptoms consistent with serotonin excess. This is observational social media data with significant limitations. But it documents real-world combinations occurring outside clinical settings.

The mechanism behind SSRI-psilocybin interactions is pharmacologically well-characterized, even though controlled clinical trials are limited. This is qualitatively different from the lab-dish-based warnings about reishi and CYP450. Serotonin syndrome has a known mechanism, a recognizable clinical presentation, and clear pharmacological logic behind the risk.

This concern does not apply to lion's mane, reishi, turkey tail, or other functional mushrooms. Those do not contain psilocybin or other serotonergic compounds. For a full analysis of psilocybin safety and the SSRI interaction in detail, see Microdosing Safety: What the Research Shows.

Which Mushrooms Carry the Greatest Drug Interaction Risk?

Based on the available evidence, here is how the commonly used medicinal mushrooms compare:

Reishi (Ganoderma lucidum) carries the most documented potential for drug interactions. Li 2024 provides specific inhibition data against seven CYP isoforms, and Kozarski 2019 documents antiplatelet activity in vitro. The breadth of potential mechanisms (CYP3A4 substrates, warfarin via CYP2C9, platelet function) puts it at the top of any honest risk ranking.

Chaga (Inonotus obliquus) has demonstrated anticoagulant properties and contains high levels of compounds that affect coagulation. It is less characterized than reishi for CYP450 interactions but presents comparable concern for blood thinner combinations.

Turkey tail (Trametes versicolor) has its primary concern in immunosuppressant combinations. Its active polysaccharide PSP shows CYP2C9 inhibition in vitro, relevant because warfarin is a CYP2C9 substrate. Its well-studied immune-modulating activity also makes it the most relevant mushroom for transplant patient questions.

Lion's mane (Hericium erinaceus) shows antiplatelet activity in vitro but lacks the CYP450 inhibition data that makes reishi the higher concern. Its primary drug interaction risk is for anticoagulant combinations. For people combining lion's mane with focus medications including stimulants, see Lion's Mane vs. Stimulant Medications for Focus: What We Know.

Maitake (Grifola frondosa) and Agaricus blazei carry concerns primarily in the diabetes drug context. Their glucose-lowering activity via alpha-glucosidase inhibition is the relevant mechanism, and the Hsu 2007 clinical trial provides the only direct RCT evidence in the field.

The Bottom Line

The research on medicinal mushroom drug interactions is best understood in evidence tiers. For chemotherapy, the picture is reassuring: 77 clinical studies found no adverse interactions when turkey tail or reishi was added to cytotoxic regimens, with documented immune and quality-of-life benefits. For diabetes medications, the one RCT combined Agaricus blazei with metformin and gliclazide and found the combination safe and beneficial. For blood thinners and CYP450-metabolized drugs, the concerns are grounded in specific laboratory findings, particularly the Li 2024 characterization of reishi triterpenoids against seven CYP isoforms and the Kozarski 2019 platelet data, but confirmed clinical interactions at supplement doses remain undocumented. The SSRI-psilocybin combination is a separate category with a well-characterized pharmacological mechanism that does not apply to functional mushrooms.

Frequently Asked Questions

Can you take mushroom supplements with medications?

For most medications, the published evidence shows no confirmed clinical interactions with functional mushrooms at typical supplement doses. The areas with the most specific laboratory evidence for potential concern are reishi with CYP450-metabolized drugs (particularly warfarin and narrow-therapeutic-window medications) and reishi or lion's mane with anticoagulants. A 2020 systematic review found mushroom extracts safe across 77 clinical trials with chemotherapy drugs, which represents the most comprehensive evidence available.

Which mushrooms interact with blood thinners?

Reishi and lion's mane have shown antiplatelet activity in laboratory studies, with reishi also inhibiting CYP2C9, the liver enzyme that metabolizes warfarin. Chaga has demonstrated anticoagulant properties in preclinical research. These findings are from lab studies rather than documented clinical bleeding events, but they provide a plausible mechanism for caution in people whose anticoagulation requires regular monitoring.

Do medicinal mushrooms affect drug metabolism?

Reishi contains compounds (triterpenoids) that inhibit multiple liver drug-processing enzymes in laboratory studies, including CYP3A4, CYP2C9, CYP2B6, and CYP2C19. A 2024 study evaluated 66 individual reishi triterpenoids against all seven major CYP enzyme types and found measurable inhibitory activity. Whether supplement doses produce concentrations high enough to affect drug metabolism in people has not been confirmed in human pharmacokinetic studies.

Is it safe to take reishi with prescription medications?

Reishi has the most extensive laboratory evidence for potential drug interactions among commonly used mushrooms, particularly for drugs metabolized by CYP3A4, CYP2C9, and related enzymes. The in vitro evidence is specific and mechanistically sound. Human clinical studies confirming interactions at typical supplement doses do not yet exist. People taking narrow-therapeutic-window medications such as warfarin or cyclosporine, where small changes in drug levels carry clinical consequences, have the most reason to weigh the laboratory data carefully.

What medications should not be taken with mushroom supplements?

No absolute contraindications between functional mushrooms and specific medications have been established in clinical trials. The drug classes with the most evidence-grounded concern based on laboratory research are anticoagulants (particularly warfarin), CYP450-metabolized drugs with narrow therapeutic windows, immunosuppressants used in transplant patients, and sulfonylurea-class diabetes drugs when combined with glucose-lowering mushrooms. SSRIs combined with psilocybin mushrooms carry a more direct serotonin syndrome risk through a separate mechanism that does not apply to functional mushrooms.

Sources & References

1. 1RTHM-01926·Li, Dawei et al. (2024). “Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs..” Frontiers in pharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00114·Hsu, Chung-Hua et al. (2007). “The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial..” Journal of alternative and complementary medicine (New York.Study breakdown →PubMed →↩
3. 3RTHM-01225·Lam, Chun Sing et al. (2020). “Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review..” Chinese medicine.Study breakdown →PubMed →↩
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.